linjc16/ctgov huggingface dataset:
Development of AI Model for Uveitis Progression and Prognosis

Study Overview
=================
Brief Summary
-----------------
Uveitis is a recurrent inflammation of the eye that can lead to vision loss with various and complicated etiologies. There are many difficulties in uveitis management due to the requirement of long-term monitoring and treatment. This study intends to establish a longitudinal cohort of uveitis patients to colloect multimodal clinical data including visual acuity, intraocular pressure, anterior segment photography, fundus photography, fluoroscopy and other ophthalmic examinations, and final diagnosis in order to use artificial intelligence and deep learning technology to extract ocular features, explore the association with the progression and prognosis of uveitis and finally establish a disease management model for uveitis.

Official Title
-----------------
Development of Artificial Intelligence Prediction Model for Uveitis Progression and Prognosis

Conditions
-----------------
Uveitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants who were diagnosed as uveitis, including the initial stage or relapse, or remission of uveitis. Exclusion Criteria: Participants who cannnot cooperate with ocualr examination.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| initial<br> | |
| relapse<br> | |
| inactive<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| uveitis progression | uveitis progression is divided into remission, relapse, or initial | up to 1 month |
Sarcopenia is an Independent Prognostic Factor for Overall Survival in Patients With Pancreatic Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study was to validate Total Psoas Area (TPA) measurement as an independent prognostic factor of overall survival in patients with pancreatic adenocarcinoma. Secondary objective was to describe the evolution of the TPA during the follow-up.

Official Title
-----------------
Sarcopenia is an Independent Prognostic Factor for Overall Survival in Patients With Pancreatic Adenocarcinoma

Conditions
-----------------
Pancreatic Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients consecutive enrolled from January 2009 to December 2015 who underwent at least one chemotherapy for pancreatic adenocarcinoma, whatever the stage Exclusion Criteria: A patient record captured outside the time frame from January 2009 to December 2015

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | 24 months |
Effects of Peptides Derived From Fermented Milk on Blood Pressure Regulation System in Healthy Volunteers.

Study Overview
=================
Brief Summary
-----------------
Several milk proteins are precursors of peptides, released during fermentation, which possess various biochemical and physiological properties. Among them, some peptides have been reported to inhibit angiotensin-converting enzyme (ACE) in vitro (an enzyme implicated in blood pressure regulation) and to lower blood pressure (BP). in hypertensive rats and in a small sample of patients with hypertension. One possible mechanism for the BP lowering effect is inhibition of ACE. Prior investigating BP lowering effect of these peptides in a large cohort of hypertensive patients, it is necessary to assess in depth their potency to inhibit ACE in vivo in humans and to compare it to that induced by a well-known ACE inhibitor.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male volunteers aged between 18 and 35 years informed written consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ACE activity |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| kinetics/dynamics |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ACE activity, Fermented milk peptides, Healthy male volunteers
Retinal Vessel Diameter in Branch Retinal Vein Occlusion

Study Overview
=================
Brief Summary
-----------------
The authors investigated the consecutive change of retinal vessel's diameter in affected eye and fellow eye of Branch Retinal Vein Occlusion.

Detailed Description
-----------------
Twenty five consecutive patients who had undergone intravitreal bevacizumab injection for Branch Retinal Vein Occlusion with macular edema were included in this study. All subjects were enrolled between April, 2012 and April, 2013 in the Department of Ophthalmology, Kyungpook National University Hospital.

Official Title
-----------------
Change of Retinal Vessel Diameter in Branch Retinal Vein Occlusion After Intravitreal Bevacizumab Injection

Conditions
-----------------
Branch Retinal Vein Occlusion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Best-corrected visual acuity less than 20/40 Central subfield macular thickness (CSMT) 300 μm or greater on spectral-domain optical coherence tomography Exclusion Criteria: Patients with recurrent BRVO History of previous treatments for BRVO including vitreoretinal surgery, intravitreal injection, subtenon injection or laser photocoagulation Patients with diabetes or dyslipidemia IOP ≥ 22mmHg, treatment for glaucoma, a family history of glaucoma, or optic neuropathy High myopia (<-6 Diopters), high hyperopia (>6 Diopters) or a history of refractive surgeries Co-existing retinal disease other than BRVO Corneal diseases include ulcer, keratoconus and a history of corneal laceration Cataract and other media opacities resulting in visual impairment or poor fundus images

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BRVO, Retinal vessel diameter<br>The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Unoccluded retinal vessel diameter of Branch Retinal Vein Occlusion | To evaluate the change of unoccluded retinal vessel diameter in affected eye of Branch Retinal Vein Occlusion and unaffected fellow eye. | 0, 1, 3, and 6 months |
a Smptomatic Bacteriuria in Pregnancy

Study Overview
=================
Brief Summary
-----------------
Asymptomatic bacteriuria (ASB) is defined as the presence of at least 105 colony-forming units (CFU)/ml of 1 or 2 bacterial species in clean-voided midstream urine sample from an individual without symptoms of UTI

Detailed Description
-----------------
ASB is common in women and increases in prevalence with age and/or sexual activity, due to short urethra, pregnancy, easy contamination of urinary tract with fecal flora The pregnant women are two times more commonly affected than age matched non pregnant females. This is due to urinary stasis due to progesterone effect in pregnancy in addition to different morphological and physiological changes occurring during pregnancy The prevalence of ASB is about 3 times higher in diabetic women (ranging from 15% to 30%) than in non-diabetic women (less than 10%)

Official Title
-----------------
a Symptomatic Bacteriuria in Pregnant Females

Conditions
-----------------
Bacteriuria in Pregnancy

Intervention / Treatment
-----------------
* Diagnostic Test: urine analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Pregnant females 2. Non-symptomatic females. Exclusion Criteria: 1. Patients taking antibiotics in the last two weeks. 2. Symptomatic UTI. 3. Suspected urinary tract abnormalities. 4. Urinary catheterization. 5. Renal dialysis.

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pregnant women in first Trimester<br>A urine sample will be taken from pregnant women before 14 weeks of pregnancy | Diagnostic Test: urine analysis<br>* Intervention is (urine analysis ): of a mid stream urine sample will be taken<br>|
| pregnant women in second Trimester<br>A urine sample will be taken from pregnant women from 14 weeks +1 day till 28 weeks | Diagnostic Test: urine analysis<br>* Intervention is (urine analysis ): of a mid stream urine sample will be taken<br>|
| pregnant women in third Trimester<br>A urine sample will be taken from pregnant women from 28 weeks +1 day till 40 weeks | Diagnostic Test: urine analysis<br>* Intervention is (urine analysis ): of a mid stream urine sample will be taken<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of participants who will discovered to have bacteriuria | Incidence of asymptomatic bacteriuria among pregnant females. | within 4 weeks |
Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases

Study Overview
=================
Brief Summary
-----------------
To assess the safety and efficacy of a single fraction of radiotherapy using helical tomotherapy to treat bone metastases.

Official Title
-----------------
Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases

Conditions
-----------------
Bone Neoplasms

Intervention / Treatment
-----------------
* Procedure: Helical tomotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: painful metastatic bone disease from any malignancy Exclusion Criteria: previous RT to same area contraindications to RT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Helical tomotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To deliver a single fraction of radiotherapy safely to patients with bone metastases using helical tomotherapy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess and quantify the acute toxicity of patients with bone metastases treated with helical tomotherapy. |  |  | 
| To measure invivo dosimetry and compare delivered doses to computer-reconstructed dose distribution. |  |  | 
| To determine the maximum tolerated does of palliative radiation give with helical tomotherapy in a single fraction. |  |  | 
| To assess the efficacy (pain control) of radiotherapy given with helical tomotherapy. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tomotherapy, bone metastases, radiotherapy, intensity modulated
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.

Detailed Description
-----------------
This is a multicenter, retrospective observational real-world study, which evaluates the efficacy of Osimertinib, between 2017 and 2022, in patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer. This study serves as the external control for a single arm phase II trial on JMT101 combined with Osimertinib in patients with Non-Small Cell Lung Cancer. The primary outcome measure is objective response rate (ORR).

Official Title
-----------------
To Evaluate Real-World Effectiveness of Osimertinib for Patients With Advanced or Metastatic Epidermal Growth Factor Receptor 20exon Insertion Mutation (20ins) Non-Small Cell Lung Cancer (NSCLC)

Conditions
-----------------
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations

Intervention / Treatment
-----------------
* Drug: Osimertinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Locally advanced or metastatic (stage ШB-Ⅳ, 8th AJCC) NSCLC confirmed by histology or cytology; The result of EGFR 20ins is positive detected by tissue, blood, pleural fluid or cerebrospinal fluid; Have received osimertinib treatment after detection of EGFR 20ins; Age of 18 years or above; Information about tumor outcome evaluation is required at least once after osimertinib treatment (such as tumor imaging data, description of efficacy evaluation in medical records, etc.). Exclusion Criteria: Previously treated with JMT101 (Patients will be included if osimertinib treatment is before JMT101 treatment); Patients harboring EGFR exon20 insertion mutation and also have other EGFR TKI-sensitizing EGFR mutations, such as G719X mutation in exon 18, exon 19 deletion mutation (19 del), exon 20 T790M or S768I mutation, exon 21 L858R mutation, or L861Q mutation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Osimertinib|80 or 160 mg/qd|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1.Real world Objective Response Rate (rwORR) |  | March 2017 to May 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Real world Duration of Response（rwDOR） |  | From March 2017 to May 2022 | 
| Real world Disease Control Rate（rwDCR） |  | From March 2017 to May 2022 | 
| Real world Progression Free Survival（rwPFS） |  | From March 2017 to May 2022 |
Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt

Study Overview
=================
Brief Summary
-----------------
Thyroxin a vital hormone for life lot of body functions depend on proper functioning on pituitary thyroid axis. it exists in two major forms Thyroxine (T4) and (T3) , each of them containing two iodine atoms on their inner (tyrosine) ring. Synthesis of reasonable quantities of thyroid hormones requires adequate iodine intake to allow sufficient thyroidal uptake. The World Health Organization (WHO) recommendation for daily intake of iodine is 150 μg for children ≥12 years and adults, and 250 μg for pregnant and lactating women. However as we know optimum amount of iodine is required for normal pituitary thyroid axis like wise excessive intake may cause over functioning of axis hence over production of hormone that can be manifested both clinically and biochemically. This study is designed to observe the frequency of over hyperthyroidism in patients taking iodinated salt.

Detailed Description
-----------------
All patients presenting to endocrine clinic fulfilling inclusion and exclusion criteria will be recruited. They will be examined, their vitals including blood pressure pulse will be noted, thyroid clinical examination including eye signs and thyroid status will be done biochemical Thyroid profile (TSH, Free T3 & Free T4) will be noted in predesigned proforma. Statistical Analysis will be done ,after data is entered in Statistical Package for the Social Sciences (SPSS) version 25 .qualitative data will be presented as frequencies and percentages while quantitative data will be presented as mean medians and standard deviations.

Official Title
-----------------
Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt: A Cross Sectional Study

Conditions
-----------------
Thyroid Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients presenting with biochemical hyperthyroidism Who are taking Iodinated salt. Treatment naïve patients Both genders included All patients who can give consent (18-60 years) Exclusion Criteria: 1) Pregnant females 2) Lactating mothers -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Affect of Iodinated Salt on Thyroid Status | Affect of Iodinated Salt on Thyroid Status | through study completion an average of 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thyroid, Iodine
Adjustment Exploratory Protocols and Functional Evaluation of New Non Invasive Devices in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
Parameters, sequences or paradigms optimisation in view of data quality and relevancy improvement.

Detailed Description
-----------------
Various tests are needed for methodological optimization of the several devices (per-operative MRI, MEG, EEG, SPECT-CT, motor platform) of the technological platform.

Official Title
-----------------
Adjustment Exploratory Protocols (MagnetoEncephaloGraphy Study : MEG, ElectroEncephaloGram : EEG, Magnetic Resonance Imaging : MRI, Functional MRI : MRIf, Motor Platform) and Functional Evaluation of New Non Invasive Devices (REX BIONICS Exoskeleton) in Healthy Volunteers

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Device: Imaging devices
* Device: New Non Invasive Devices


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers Male or female aged over 18 years Registered in the French social security scheme Signed informed consent Exclusion Criteria: Contraindication to Magnetoencephalography (MEG) and/or Electroencephalography (EEG) Contraindication to Magnetic resonance imaging (MRI) All categories of protected persons

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: healthy volunteers<br>Imaging devices New Non Invasive Devices | Device: Imaging devices<br>* technological adjustment tests<br>Device: New Non Invasive Devices<br>* Tests with REX BIONICS Exoskeleton<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Magnetic brain activity | MEG records | 2 hours | 
| Brain imaging | MRI and SPECT-CT records | 2 hours | 
| Electrical brain activity | EEG records | 2 hours | 
| Motor activity parameters | Motor platform records | 2 hours |
A Midazolam Drug Interaction Study With PF-04171327

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effects of multiple doses of PF-04171327 on the blood levels (pharmacokinetics) of midazolam

Official Title
-----------------
A Phase 1, Open Label, Multiple Dose Study Of The Effect Of PF-04171327 On Midazolam Pharmacokinetics In Healthy Volunteers

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: PF-04171327 25 mg
* Drug: Midazolam 2 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males and/or females (non-childbearing potential) volunteers. Cortisol level within normal reference range of the laboratory. Exclusion Criteria: History of intolerance or significant adverse effect with glucocorticoid (steroid) therapy. History or current positive results for HIV, Hepatitis B or C or active TB or currently undergoing treatment for TB. Known history of hypersensitivity, allergy severe drug reaction or unable to tolerate midazolam or other benzodiazepines.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: PF-04171327 and Midazolam<br> | Drug: PF-04171327 25 mg<br>* One 25 mg tablet administered once a day for 15 days<br>Drug: Midazolam 2 mg<br>* Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf of midazolam |  | 17 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUClast, Cmax, Tmax, t1/2 |  | 17 days | 
| Vital Signs, Clinical Laboratory tests and Adverse Events |  | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
drug interaction CYP3A4 glucocorticoids midazolam